May influence metabolism in concomitant w/ CYP2C9 inducers (eg, rifampicin) or inhibitors (eg, fluconazole). Increased AUC w/ fluconazole. Potentiation of the blood glucose-lowering effect by phenylbutazone, azapropazone, oxyfenbutazone, insulin & oral antidiabetic (eg, metformin), salicylates, p-aminosalicylic acid, anabolic steroids & male sex hormones, chloramphenicol, certain long-acting sulfonamides, tetracyclines, quinolone antibiotics & clarithromycin, coumarin anticoagulants, fenfluramine, disopyramide, fibrates, ACE inhibitors, fluoxetine, MAOIs, allopurinol, probenecid, sulfinpyrazone, sympatholytics, cyclophosphamide, trophosphamide & iphosphamides, miconazole, fluconazole, pentoxifylline (high dose parenteral), tritoqualine. Weakening of the blood glucose-lowering effect by oestrogens & progestogens; saluretics, thiazide diuretics; thyroid stimulating agents, glucocorticoids; phenothiazine derivatives, chlorpromazine; adrenaline & sympathicomimetics; nicotinic acid (high doses) & nicotinic acid derivatives; laxatives (long term use); phenytoin, diazoxide; glucagon, barbiturates & rifampicin; acetazolamide. May potentiate or weaken blood glucose-lowering effect by H2
-antagonists, β-blockers, clonidine, guanethidine & reserpine. Alcohol intake may potentiate or weaken the hypoglycaemic action. May potentiate or weaken the effects of coumarin derivatives. Reduced GIT absorption w/ colesevelam.